WAS and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, we described a new tumor-suppressor activity for WASP and demonstrated that its expression in CML interferes with BCR–ABL1-mediated signaling transduction, increases the sensitivity of leukemic cells to apoptosis and is associated with a better prognosis of CML patients.